Myelitis

Summary

Myelitis (MONDO:0002565) is a disease and 5 clinical trials. Top therapeutic interventions include methotrexate, methylprednisolone, and interferon beta. A subtype of spinal cord disorder — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 5

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	myelitis
Mondo ID	MONDO:0002565
EFO	EFO:1001472
MeSH	D009187
DOID	DOID:322
ICD-11	1993728609
NCIT	C26832
SNOMED CT	41370002
UMLS	C0026975
MedGen	10230
Is cancer (heuristic)	no

Also known as: inflammation of spinal cord · spinal cord inflammation

Disease family

This is a subtype of spinal cord disorder. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › nervous system disorder › central nervous system disorder › spinal cord disorder › myelitis

Related subtypes (9): vascular myelopathy, anterior horn disorder, tethered spinal cord syndrome, spina bifida, syringomyelia, radiation myelitis, spinal cord neoplasm, spinal cord injury, segmental spinal dysgenesis

Subtypes (4): acute transverse myelitis, poliomyelitis, transverse myelitis, acute flaccid myelitis

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 5.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	3
PHASE4	1
PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00037115	PHASE4	WITHDRAWN	Induction Therapy With a Single High Dose Bolus of Intravenous Methotrexate With Leucovorin Rescue, Prior to Initiation of AVONEX® Treatment, in Patients Presenting With a First Acute Demyelinating Event.
NCT07100990	PHASE3	RECRUITING	Treatment of Inflammatory Myelitis and Optic Neuritis With Early vs Rescue Plasma Exchange (TIMELY-PLEX)
NCT07251049	Not specified	RECRUITING	Acute Infectious Encephalitis and Myelitis in Guadeloupe by New Generation Sequencing
NCT00069303	Not specified	COMPLETED	Natural History of West Nile Virus Infection
NCT03206541	Not specified	COMPLETED	Neurologic Manifestations of the Arbovirus Infection in Colombia

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
METHOTREXATE	4	1
METHYLPREDNISOLONE	4	1
INTERFERON BETA	3	1
CHEMBL426	0	1